Literature DB >> 3418129

A sensitive radioimmunoprecipitation assay for human immunodeficiency virus (HIV).

A Pinter1, W J Honnen.   

Abstract

A sensitive and efficient radioimmunoprecipitation procedure is described which provides an alternative to Western blotting assays for characterizing antibodies directed against human immunodeficiency viruses (HIV-1). Reaction of solubilized preparations of HTLV-III with 125I-labeled Bolton-Hunter reagent leads to the efficient labeling of all of the major virus-specific proteins, including gp120, gp41, RT (p66/p51), p24, and p17. These labeled proteins are readily immunoprecipitated by immune human sera, by specific sera derived from hyperimmunized animals, and by monoclonal antibodies. This procedure, referred to as BH-RIP, provides a simple assay for characterizing and titering antibodies against HIV which is equivalent in specificity, and more sensitive and efficient than the Western blotting method. In addition, viral proteins labeled in this way are suitable for biochemical studies. In one such application, the number of high-mannose and complex oligosaccharide side chains of gp120 and gp41 were determined by examining the sensitivities of the two viral glycoproteins labeled by this procedure to the glycosidases Endo H and PNGase F.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418129     DOI: 10.1016/0022-1759(88)90363-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response.

Authors:  J S Andris; S Johnson; S Zolla-Pazner; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

2.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  M K Gorny; J Y Xu; V Gianakakos; S Karwowska; C Williams; H W Sheppard; C V Hanson; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.

Authors:  F Shang; H Huang; K Revesz; H C Chen; R Herz; A Pinter
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.

Authors:  M A Till; S Zolla-Pazner; M K Gorny; J S Patton; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Quantitation of antibody reactivity to human immunodeficiency virus (type 1) proteins and glycoproteins on Western immunoblots by reflectance densitometry.

Authors:  C T Hardy; T A Damrow; G E Kenny
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

7.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.

Authors:  Tobias Wolk; Michael Schreiber
Journal:  Med Microbiol Immunol       Date:  2006-03-18       Impact factor: 3.402

9.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.